Friday, July 04, 2025 | 02:34 PM ISTहिंदी में पढें
ERIS Lifesciences Ltd News
Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%_24650
The company launched four new products in the first nine months of FY22, more on the anvil
 "Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%_24650")
Updated On : 28 Jan 2022 | 6:49 PM IST
Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment_3788
The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement
 "Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment_3788")
Updated On : 06 Dec 2021 | 9:35 AM IST
